Safety and efficacy of dexmedetomidine for postoperative sedation in the ICU, after endoscopic submucosa dissection under general anesthesia.

Safety and efficacy of dexmedetomidine for postoperative sedation in the ICU, after endoscopic submucosa dissection under general anesthesia. - Safety efficacy of dexmedetomidine for postoperative sedation in the ICU, after endoscopic submucosa dissection under general anesthesia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009980

Enrollment

Registered

2013-02-06

Start date

2013-02-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical esophageal cancer pharyngeal cancer

Interventions

Hight dose of dexmedetomidine Low dose of dexmedetomidine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: To undergo ESD under general anesthesia. To keep inubated until the next morning in the intensive care unit. Consenting patients

Exclusion criteria

Exclusion criteria: ASA class >3. BMI <35. Routine oral administration of sedatives and analgesics. Drug allergy of dexmedetomidine

Design outcomes

Primary

Measure	Time frame
respiration, hemodynamic, complication, RASS score, VRS, the number of sedatives and analgesics, the number of fentanyl IV-PCA, questionnair	—

Countries

Japan

Contacts

Public ContactChika Ishibashi

Juntendo university Anesthesiology

03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026